Suppr超能文献

在一名患有慢性神经内脏酸性鞘磷脂酶缺乏症的儿童中对olipudase alfa诱导的过敏反应进行脱敏治疗。

Desensitization of olipudase alfa-induced anaphylaxis in a child with chronic neurovisceral acid sphingomyelinase deficiency.

作者信息

Fiori Laura, Tagi Veronica Maria, Montanari Chiara, Gambino Mirko, Carlevatti Veronica, Zizzo Carmela, D'Auria Enza, Dilillo Dario, Verduci Elvira, Zuccotti Gianvincenzo

机构信息

Department of Pediatrics, Buzzi Children's Hospital, Milan, Italy.

Department of Biomedical and Clinical Science, University of Milan, Milan, Italy.

出版信息

Mol Genet Metab Rep. 2024 Jul 17;40:101120. doi: 10.1016/j.ymgmr.2024.101120. eCollection 2024 Sep.

Abstract

UNLABELLED

Olipudase alfa is indicated for the non-central nervous system manifestations of Acid sphingomyelinase deficiency (ASMD). Anaphylaxis is a very rare and life-threatening adverse reaction described for this drug. Here, we report the case of a 2-year-old boy affected by chronic neurovisceral ASMD who experienced signs of hypersensitivity reactions to olipudase alfa since the administered dose of 1 mg/kg during dose escalation and a proper anaphylactic reaction during the second administration of the target therapeutic dose of 3 mg/kg. The treatment was stopped for 15 weeks and then a 7-step desensitization protocol with the infused dose of 0.03 mg/kg was applied. Subsequent gradual dose escalation was resumed, successfully reaching the dose of 0.3 mg/kg. Moreover, biochemical, and radiological disease indexes, which were increased during treatment discontinuation, have gradually improved since the restart of treatment. However, at the second administration of the dose of 0.6 mg/kg, the patient experienced another adverse drug reaction with facial urticarial rash and bronchospasm, requiring the administration of adrenaline, methylprednisolone, and inhaled salbutamol. This case report highlights the need to customize the olipudase alfa desensitization protocol according to individual tolerance and raises the issue of achieving the established therapeutic target in the most sensitive children.

SYNOPSIS

We report a case of anaphylaxis to olipudase alfa in a child affected by chronic neurovisceral Acid sphingomyelinase deficiency (ASMD) and describe a 7-step desensitization procedure. This procedure, with the total administered dose of 0.03 mg/kg, followed by gradual dose escalation, allowed to reach the dose of 0.3 mg/kg without adverse reactions; however, at the second administration of the dose of 0.6 mg/kg our patient presented another adverse reaction suggesting the need of a different desensitization strategy.

摘要

未标注

奥立普酶α适用于酸性鞘磷脂酶缺乏症(ASMD)的非中枢神经系统表现。过敏反应是该药物描述的一种非常罕见且危及生命的不良反应。在此,我们报告一例2岁患有慢性神经内脏型ASMD的男孩病例,该男孩自剂量递增期间给予1mg/kg剂量的奥立普酶α后出现过敏反应迹象,并在第二次给予目标治疗剂量3mg/kg时出现了严重过敏反应。治疗中断15周,然后应用了一种7步脱敏方案,输注剂量为0.03mg/kg。随后恢复逐渐递增剂量,成功达到0.3mg/kg的剂量。此外,在治疗中断期间升高的生化和放射学疾病指标自重新开始治疗后逐渐改善。然而,在第二次给予0.6mg/kg剂量时,患者又出现了另一种药物不良反应,表现为面部荨麻疹皮疹和支气管痉挛,需要给予肾上腺素、甲泼尼龙和吸入沙丁胺醇。本病例报告强调了根据个体耐受性定制奥立普酶α脱敏方案的必要性,并提出了在最敏感儿童中实现既定治疗目标的问题。

摘要

我们报告一例患有慢性神经内脏型酸性鞘磷脂酶缺乏症(ASMD)的儿童对奥立普酶α过敏的病例,并描述了一种7步脱敏程序。该程序给予的总剂量为0.03mg/kg,随后逐渐递增剂量,在无不良反应的情况下达到了0.3mg/kg的剂量;然而,在第二次给予0.6mg/kg剂量时,我们的患者出现了另一种不良反应,提示需要不同的脱敏策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5afc/11286986/532519137b4f/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验